Rigel Pharmaceuticals, Inc. Stock News

Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech peers, despite a 186% YTD stock rise and robust 2025 sales guidance, making it a contrarian BUY. Continued momentum in Tavalisse and emerging growth from Rezlidhia position RIGL for potential outperfo...

SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 8:30 am ET.

This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimens Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient in the CONNECT TarGeT-D stud...

SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m.

Rigel Pharmaceuticals, Inc. ( RIGL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Raymond Furey - Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Raul Rodriguez - President, CEO & Director David Santos - Executive VP & Chief Commercial Officer Lisa Rojkjaer - Executive VP & Chief Medical Officer Dean Schorno - Executive VP & CFO Conferenc...

Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million  Generated $27.9 million of net income in the third quarter of 2025 Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansion phase of the ongoing Phase 1b study evaluating R289...

Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Four poster presentations will exhibit new REZLIDHIA® (olutasidenib) data in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercia...